Topic: What More We can do on Hepatitis C?

Download All Articles

A special issue of Hepatoma Research  (Print ISSN:2394-5079; Online ISSN:2454-2520).

Deadline for manuscript submissions: 30 Apr 2018

Share This Special Issue

Guest Editor(s)

  • Necati Örmeci, MD
    Department of Gastroenterology, Ankara University Medical School, Ankara, Turkey.


Special Issue Introduction:

Hepatitis C virus (HCV) is an enveloped virus with a 9.6 kb single stranded RNA genome. Six HCV genotypes and a large number of subtypes have been identified HCV is an important world-wide health and economic problem through direct and indirect medical cost associated with managing liver disease, decreased work productivity. A hundred eighty million people are infected with HCV in the world. It is thecause of acute hepatitis, chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Besides that, it may results in extra-hepatic manifestations such as mixed cryoglobulinemia, chronic kidney disease, porphyria cutaneatarda, and type 2 diabetes mellitus, rheumatoid-like nondestructive inflammatory arthritis and depression. HCV is associated with the increasing liver related and all causes of mortality.
HCV is one of the important factors (20 % of all causes) for developing the HCC. Almost 700,000 persons died from HCC in a year. HCC is the 6th most common cancer but third common cause of death from the cancer.
Those are the reasons that we made a plan to have a Special Issue about “What More We can do on Hepatitis C?”. It is hoped that this Special Issue will bring novel insights and new solutions to the liver cancer research filed.

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 30 Apr 2018
Contacts: Siqi Li, Assistant Editor,

Published Articles Download All Articles
  • Ablative techniques in hepatocellular carcinoma treatment

    Ehsun Naeem , Shahab Abid
    Hepatocellular carcinoma has been known to arise commonly in the setting of chronic liver disease. Due to its association with cirrhosis, patients with hepatocellular carcinoma often present with markedly diminished hepatic functional reserve, making them poor surgical candidates. For such patients, image-guided percutaneous ablative modalities have provided a viable alternate curative therapy. Although treatment allocation is a decision based on a number of factors, patients eligible for percutaneous ablation generally include those with early stage disease, hepatocellular carcinoma with... Read more
    This article belongs to the Special Issue What More We can do on Hepatitis C?
    Hepatoma Res 2018;4:18. | doi:10.20517/2394-5079.2018.22
    Published on: 13 Jun 2018  | Viewed:65  | Downloaded:10
    +HTML| PDF
Hepatoma Research ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.